Innate and adaptive immune responses in the CNS

The Lancet Neurology

Volumn 14, Issue 9, 2015, Pages 945-955

  Waisman, Ari ^a   Liblau, Roland S ^b   Becher, Burkhard ^c  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b France   (France)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLAMMASOME; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6;

ADAPTIVE IMMUNITY; AMYOTROPHIC LATERAL SCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL ACTIVATION; CELL DESTRUCTION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DISEASE COURSE; DRUG TARGETING; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOSURVEILLANCE; INFLAMMATION; INNATE IMMUNITY; MICROGLIA; MOTONEURON; MYELOOPTIC NEUROPATHY; NERVE REGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARANEOPLASTIC SYNDROME; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TISSUE REACTION; TISSUE REGENERATION; ANIMAL; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; IMMUNOLOGY; PATHOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; IMMUNITY, INNATE;

EID: 84939500270     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00141-6     Document Type: Review

References (117)

1. Murphy JB, Sturm E Conditions determining the transplantability of tissues in the brain. J Exp Med 1923, 38:183-197.
2. Greter M, Heppner FL, Lemos MP, et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005, 11:328-334.
3. McMenamin PG Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J Comp Neurol 1999, 405:553-562.
4. Bartholomäus I, Kawakami N, Odoardi F, et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009, 462:94-98.
5. de Vos AF, van Meurs M, Brok HP, et al. Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J Immunol 2002, 169:5415-5423.
6. Locatelli G, Wortge S, Buch T, et al. Primary oligodendrocyte death does not elicit anti-CNS immunity. Nat Neurosci 2012, 15:543-550.
7. Becher B Central nervous system immune surveillance: on natalizumab, dendritic cells, and dangerous immune privilege. Arch Neurol 2008, 65:1566-1567.
8. Lemaitre B The road to Toll. Nat Rev Immunol 2004, 4:521-527.
9. Hirano M, Das S, Guo P, Cooper MD The evolution of adaptive immunity in vertebrates. Adv Immunol 2011, 109:125-157.
10. Obermeier B, Daneman R, Ransohoff RM Development, maintenance and disruption of the blood-brain barrier. Nat Med 2013, 19:1584-1596.
11. Bentivoglio M, Kristensson K Tryps and trips: cell trafficking across the 100-year-old blood-brain barrier. Trends Neurosci 2014, 37:325-333.
12. Alvarez JI, Katayama T, Prat A Glial influence on the blood brain barrier. Glia 2013, 61:1939-1958.
13. Chaboub LS, Deneen B Developmental origins of astrocyte heterogeneity: the final frontier of CNS development. Dev Neurosci 2012, 34:379-388.
14. Finsen B, Owens T Innate immune responses in central nervous system inflammation. FEBS Lett 2011, 585:3806-3812.
15. Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330:841-845.
16. Simard AR, Soulet D, Gowing G, Julien J-P, Rivest S Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006, 49:489-502.
17. Mildner A, Schmidt H, Nitsche M, et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci 2007, 10:1544-1553.
18. Paolicelli RC, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for normal brain development. Science 2011, 333:1456-1458.
19. Sierra A, Abiega O, Shahraz A, Neumann H Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis. Front Cell Neurosci 2013, 7:6.
20. Yona S, Kim KW, Wolf Y, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 2013, 38:79-91.
21. Heppner FL, Greter M, Marino D, et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 2005, 11:146-152.
22. Kettenmann H, Kirchhoff F, Verkhratsky A Microglia: new roles for the synaptic stripper. Neuron 2013, 77:10-18.
23. Becher B, Prat A, Antel JP Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia 2000, 29:293-304.
24. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015, 14:388-405.
25. Gratwicke J, Jahanshahi M, Foltynie T Parkinson's disease dementia: a neural networks perspective. Brain 2015, 138:1454-1476.
26. McGeer PL, McGeer EG Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002, 26:459-470.
27. Bergold PJ Treatment of traumatic brain injury with anti-inflammatory drugs. Exp Neurol 2015, published online June 23, 2015. 10.1016/j.expneurol.2015.05.024.
28. Gomez-Nicola D, Fransen NL, Suzzi S, Perry VH Regulation of microglial proliferation during chronic neurodegeneration. J Neurosci 2013, 33:2481-2493.
29. Clifford DB, Ances BM HIV-associated neurocognitive disorder. Lancet Infect Dis 2013, 13:976-986.
30. Ferrer I, Aubourg P, Pujol A General aspects and neuropathology of X-linked adrenoleukodystrophy. Brain Pathol 2010, 20:817-830.
31. Krumholz A, Stern BJ Neurologic manifestations of sarcoidosis. Handb Clin Neurol 2014, 119:305-333.
32. Derecki NC, Cronk JC, Lu Z, et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 2012, 484:105-109.
33. Lee-Kirsch MA, Wolf C, Gunther C Aicardi-Goutieres syndrome: a model disease for systemic autoimmunity. Clin Exp Immunol 2014, 175:17-24.
34. Rice GI, del Toro Duany Y, Jenkinson EM, et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 2014, 46:503-509.
35. Joubert B, Honnorat J Autoimmune channelopathies in paraneoplastic neurological syndromes. Biochim Biophys Acta 2015, published online April 14, 2015. 10.1016/j.bbamem.2015.04.003.
36. Hemmer B, Kerschensteiner M, Korn T Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol 2015, 14:406-419.
37. Tenembaum SN Acute disseminated encephalomyelitis. Handb Clin Neurol 2013, 112:1253-1262.
38. Liblau RS, Vassalli A, Seifinejad A, Tafti M Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol 2015, 14:318-328.
39. Varadkar S, Bien CG, Kruse CA, et al. Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol 2014, 13:195-205.
40. Pignolet BS, Gebauer CM, Liblau RS Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: A beneficial antitumor immune response going awry. Oncoimmunology 2013, 2:e27384.
41. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998, 4:1321-1324.
42. Leyhe T, Schüle R, Schwärzler F, Gasser T, Haarmeier T Second primary tumour in anti-Ma1/2-positive paraneoplastic limbic encephalitis. J Neurooncology 2006, 17:49-51.
43. Baizabal-Carvallo JK, Jankovic J Stiff-person syndrome: insights into a complex autoimmune disorder. J Neurol Neurosurg Psychiatry 2015, 86:840-848.
44. Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012, 135:1622-1638.
45. Simon NG, Parratt JD, Barnett MH, et al. Expanding the clinical, radiological and neuropathological phenotype of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). J Neurol Neurosurg Psychiatry 2012, 83:15-22.
46. Scheikl T, Pignolet B, Dalard C, et al. Cutting edge: neuronal recognition by CD8 T cells elicits central diabetes insipidus. J Immunol 2012, 188:4731-4735.
47. Bruck W, Popescu B, Lucchinetti CF, et al. Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Ann Neurol 2012, 72:385-394.
48. Jeltsch-David H, Muller S Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat Rev Neurol 2014, 10:579-596.
49. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010, 30:5866-5875.
50. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009, 65:424-434.
51. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010, 9:776-785.
52. B receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013, 81:1500-1506.
53. A receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014, 13:276-286.
54. Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008, 71:1291-1292.
55. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010, 133:2734-2748.
56. Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014, 13:575-586.
57. Prokop S, Miller KR, Heppner FL Microglia actions in Alzheimer's disease. Acta Neuropathol 2013, 126:461-477.
58. Boillee S, Vande Velde C, Cleveland DW ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
59. Beers DR, Henkel JS, Zhao W, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 2011, 134:1293-1314.
60. Vehvilainen P, Koistinaho J, Gundars G Mechanisms of mutant SOD1 induced mitochondrial toxicity in amyotrophic lateral sclerosis. Front Cell Neurosci 2014, 8:126.
61. Garbuzova-Davis S, Sanberg PR Blood-CNS Barrier Impairment in ALS patients versus an animal model. Front Cell Neurosci 2014, 8:21.
62. Wijesekera LC, Leigh PN Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009, 4:3.
63. Sreedharan J, Brown RH Amyotrophic lateral sclerosis: Problems and prospects. Ann Neurol 2013, 74:309-316.
64. Varvel NH, Grathwohl SA, Baumann F, et al. Microglial repopulation model reveals a robust homeostatic process for replacing CNS myeloid cells. Proc Natl Acad Sci USA 2012, 109:18150-18155.
65. Butovsky O, Siddiqui S, Gabriely G, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest 2012, 122:3063-3087.
66. Gowing G, Dequen F, Soucy G, Julien JP Absence of tumor necrosis factor-alpha does not affect motor neuron disease caused by superoxide dismutase 1 mutations. J Neurosci 2006, 26:11397-11402.
67. Yamanaka K, Boillee S, Roberts EA, et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci USA 2008, 105:7594-7599.
68. Lee JK, Tran T, Tansey MG Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol 2009, 4:419-429.
69. Ransohoff RM, Perry VH Microglial physiology: unique stimuli, specialized responses. Ann Rev Immunol 2009, 27:119-145.
70. Hirsch EC, Hunot S Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009, 8:382-397.
71. Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005, 19:533-542.
72. Roodveldt C, Labrador-Garrido A, Gonzalez-Rey E, et al. Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants. PLoS One 2010, 5:e13481.
73. Biber K, Owens T, Boddeke E What is microglia neurotoxicity (Not)?. Glia 2014, 62:841-854.
74. Martin-Blondel G, Delobel P, Blancher A, et al. Pathogenesis of the immune reconstitution inflammatory syndrome affecting the central nervous system in patients infected with HIV. Brain 2011, 134:928-946.
75. Martin-Blondel G, Bauer J, Cuvinciuc V, et al. In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection. Neurology 2013, 81:964-970.
76. Nylander A, Hafler DA Multiple sclerosis. J Clin Invest 2012, 122:1180-1188.
77. Steinman L Immunology of relapse and remission in multiple sclerosis. Ann Rev Immunol 2014, 32:257-281.
78. Liblau RS, Gonzalez-Dunia D, Wiendl H, Zipp F Neurons as targets for T cells in the nervous system. Trends Neurosci 2013, 36:315-324.
79. Monstad SE, Knudsen A, Salvesen HB, Aarseth JH, Vedeler CA Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother 2009, 58:1795-1800.
80. Rauer S, Kaiser R Demonstration of anti-HuD specific oligoclonal bands in the cerebrospinal fluid from patients with paraneoplastic neurological syndromes. Qualitative evidence of anti-HuD specific IgG-synthesis in the central nervous system. J Neuroimmunol 2000, 111:241-244.
81. Wanschitz J, Hainfellner JA, Kristoferitsch W, Drlicek M, Budka H Ganglionitis in paraneoplastic subacute sensory neuronopathy: a morphologic study. Neurology 1997, 49:1156-1159.
82. Yamasaki R, Lu H, Butovsky O, et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J Exp Med 2014, 211:1533-1549.
83. Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre JY Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol 1999, 45:162-167.
84. Roberts WK, Deluca IJ, Thomas A, et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest 2009, 119:2042-2051.
85. Saadoun S, Waters P, MacDonald C, et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol 2012, 71:323-333.
86. Misu T, Hoftberger R, Fujihara K, et al. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 2013, 125:815-827.
87. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
88. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473-477.
89. Papadopoulos MC, Verkman AS Aquaporin water channels in the nervous system. Nat Rev Neurosci 2013, 14:265-277.
90. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009, 66:617-629.
91. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011, 108:3701-3706.
92. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009, 66:630-643.
93. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133:349-361.
94. Zhang H, Verkman AS Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest 2013, 123:2306-2316.
95. Hinson SR, Romero MF, Popescu BF, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci USA 2012, 109:1245-1250.
96. Marignier R, Nicolle A, Watrin C, et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 2010, 133:2578-2591.
97. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002, 58:143-146.
98. Sabater L, Giralt A, Boronat A, et al. Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol 2009, 215:31-35.
99. Kuroda H, Fujihara K, Takano R, et al. Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol 2013, 254:178-182.
100. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013, 12:554-562.
101. Ratelade J, Zhang H, Saadoun S, Bennett JL, Papadopoulos MC, Verkman AS Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol 2012, 123:861-872.
102. Krishnamoorthy G, Saxena A, Mars LT, et al. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat Med 2009, 15:626-632.
103. Birnbaum ME, Mendoza JL, Sethi DK, et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 2014, 157:1073-1087.
104. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 2012, 72:53-64.
105. Haghikia A, Hohlfield R, Gold R, Fugger L Therapies for multiple sclerosis: translational achievements and outstanding needs. Trends Mol Med 2013, 19:309-319.
106. Rothhammer V, Muschaweckh A, Gasteiger G, et al. alpha4-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets. Acta Neuropathol Commun 2014, 2:27.
107. Giacomini PS, Rozenberg A, Metz I, et al. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med 2014, 370:486-488.
108. Martin-Blondel G, Bauer J, Uro-Coste E, et al. Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8 T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome. Acta Neuropathol 2015, 129:463-465.
109. Lu DR, Robinson WH Street-experienced peripheral B cells traffic to the brain. Sci Transl Med 2014, 6:248fs31.
110. Bielekova B Daclizumab therapy for multiple sclerosis. Neurotherapeutics 2013, 10:55-67.
111. Walsh JG, Muruve DA, Power C Inflammasomes in the CNS. Nat Rev Neurosci 2014, 15:84-97.
112. Vom Berg J, Prokop S, Miller KR, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med 2012, 18:1812-1819.
113. Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014, 383:2213-2221.
114. Dolgin E The inverse of immunity. Nat Med 2010, 16:740-743.
115. Lutterotti A, Yousef S, Sputtek A, et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med 2013, 5:188ra75.
116. Tradtrantip L, Zhang H, Saadoun S, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012, 71:314-322.
117. Schwartz M, Raposo C Protective autoimmunity: a unifying model for the immune network involved in CNS repair. Neuroscientist 2014, 20:343-358.